AU-002 / Dr. Reddy’s - LARVOL DELTA

Rademikibart (IL-4Rα Blocker) Integrated Exposure-Response Analysis Supports Differentiated Once Monthly Dosing Regimen (EADV 2024) - P2 | "Materials & Briefly, the ER analysis incorporated one specific e ff icacy assessment, EASI, from two clinical studies, including one Phase 1b study (Study CBP-201-AU002) and one Phase 2 study (Study CBP-201- CN002 (Stage 1)) . In conclusion, the recommended Phase 3 once monthly dose and schedule (300 mg Q4W) is optimal as it maximizes the probability of EASI-75 response achieved early in treatment with no added safety risk and maintains comparable Week 16 efficacy to the 300 mg Q2W regimen."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL4R